PE20090211A1 - Inhibidores de las iap - Google Patents

Inhibidores de las iap

Info

Publication number
PE20090211A1
PE20090211A1 PE2008000757A PE2008000757A PE20090211A1 PE 20090211 A1 PE20090211 A1 PE 20090211A1 PE 2008000757 A PE2008000757 A PE 2008000757A PE 2008000757 A PE2008000757 A PE 2008000757A PE 20090211 A1 PE20090211 A1 PE 20090211A1
Authority
PE
Peru
Prior art keywords
alkyl
members
heterocicle
carbocycle
mercapto
Prior art date
Application number
PE2008000757A
Other languages
English (en)
Inventor
John A Flygare
Frederick Cohen
Kurt Deshayes
Michael F T Koehler
Lewis J Gazzard
Lan Wang
Chudi Ndubaku
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39926122&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090211(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20090211A1 publication Critical patent/PE20090211A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA U1-M-U2; EN EL QUE U1 Y U2 SON DE FORMULA I, DONDE X1 Y X2 SON O O S; R2 ES ISOPROPILO, CICLOHEXILO, TETRAHIDROPIRAN-4-ILO, ENTRE OTROS; R3 ES H, (C1-C4)ALQUILO O FORMAR CON R4 UN HETEROCICLO DE 3 A 6 MIEMBROS; R3' ES H O JUNTO A R3 FORMAN UN CARBOCICLO DE 3 A 6 MIEMBROS; R4 Y R4' SON H, AMINO, METILO, MERCAPTO, HETEROCICLOALQUILO, ENTRE OTROS; R5 ES H O METILO; G ES SELECCIONADO DE IVa, IVe, ENTRE OTROS, DONDE R1 ES H, OH, ALQUILO O FORMAR CON R2 UN HETEROCICLO DE 5 A 8 MIEMBROS; R5' ES H O ALQUILO; R6 Y R6' SON H, ALQUILO, ARILO O ARALQUILO; R7 ES H, CIANO, MERCAPTO, GUANIDINO, ENTRE OTROS; n ES DE 1 A 4; R9' ES H, ALQUILO, CARBOCICLO, ENTRE OTROS; X3 ES O O S; Y ES UN ENLACE (CR7R7)n', O O S; n' ES 1 O 2; R7 ES H, HALOGENO, ARILO, ENTRE OTROS; M ES -CH2-[C=C]0-4-CH2-, -(CH2)1-14, ENTRE OTROS. SON SELECCIONADOS: ACIDO 2-[TERT-BUTOXICARBONIL-(1H-PIRROL-2-ILMETIL)-AMINO]-PROPIONICO, ACIDO 2(S)-[[(2-(4'-FLUORO(1,1'-BIFENIL))AMINO]CARBONIL]-1-(1,1-DIMETILETILESTER)-1-PIRROLIDINOCARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS PROTEINAS DE APOPTOSIS UTILES EN EL TRATAMIENTO DE NEOPLASIAS MALIGNAS
PE2008000757A 2007-04-30 2008-04-29 Inhibidores de las iap PE20090211A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91501007P 2007-04-30 2007-04-30

Publications (1)

Publication Number Publication Date
PE20090211A1 true PE20090211A1 (es) 2009-04-02

Family

ID=39926122

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008000757A PE20090211A1 (es) 2007-04-30 2008-04-29 Inhibidores de las iap
PE2012001805A PE20130150A1 (es) 2007-04-30 2008-04-29 Inhibidores de las iap

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012001805A PE20130150A1 (es) 2007-04-30 2008-04-29 Inhibidores de las iap

Country Status (18)

Country Link
US (1) US8907092B2 (es)
EP (1) EP2148858A4 (es)
JP (1) JP5368428B2 (es)
KR (1) KR20100024923A (es)
CN (1) CN101687787A (es)
AR (1) AR066348A1 (es)
AU (1) AU2008245447C1 (es)
BR (1) BRPI0809867A2 (es)
CA (1) CA2683392A1 (es)
CL (1) CL2008001234A1 (es)
IL (1) IL201379A0 (es)
MX (1) MX2009011783A (es)
NZ (2) NZ598890A (es)
PE (2) PE20090211A1 (es)
RU (1) RU2491276C2 (es)
TW (1) TWI432212B (es)
WO (1) WO2008134679A1 (es)
ZA (1) ZA200906946B (es)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
NZ589670A (en) * 2004-12-20 2013-01-25 Genentech Inc Pyrrolidine inhibitors of iap
CA2598995C (en) 2005-02-25 2014-07-15 Stephen M. Condon Dimeric iap inhibitors
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
RU2418807C2 (ru) 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US7985735B2 (en) 2006-07-24 2011-07-26 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
AU2009203971A1 (en) * 2008-01-11 2009-07-16 Genentech, Inc. Inhibitors of IAP
EP2250160B1 (en) 2008-01-25 2015-11-11 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
CA2730448A1 (en) 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
AU2010254056A1 (en) 2009-05-28 2011-12-15 Tetralogic Pharmaceuticals Corp. IAP inhibitors
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
CN102822175A (zh) 2009-12-18 2012-12-12 埃迪尼克斯医药公司 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
AR082665A1 (es) 2010-08-11 2012-12-26 Millennium Pharm Inc Derivados heteroarilicos inhibidores de quinasas pi3k, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos proliferativos, inflamatorios y/o cardiovasculares
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
SG189396A1 (en) 2010-10-13 2013-05-31 Millennium Pharm Inc Heteroaryls and uses thereof
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
NO2755614T3 (es) 2012-01-03 2018-03-31
RU2666530C2 (ru) 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
WO2013166344A1 (en) 2012-05-04 2013-11-07 Novartis Ag Biomarkers for iap inhibitor therapy
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
AU2014235474B2 (en) 2013-03-15 2017-05-25 Novartis Ag Antibody drug conjugates
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
CN106659790A (zh) 2014-08-12 2017-05-10 诺华股份有限公司 抗cdh6抗体药物缀合物
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
KR102110566B1 (ko) 2015-01-20 2020-05-13 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
IL290809B2 (en) 2016-11-01 2024-01-01 Arvinas Operations Inc PROTACS Targeted Tau-Protein and Related Methods of Use
IL297717A (en) 2016-12-01 2022-12-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
BR112019012682A2 (pt) 2016-12-23 2019-12-17 Arvinas Operations Inc moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
KR20230119252A (ko) 2016-12-23 2023-08-16 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를위한 화합물 및 방법
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN117551089A (zh) 2017-01-26 2024-02-13 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US11179413B2 (en) 2017-03-06 2021-11-23 Novartis Ag Methods of treatment of cancer with reduced UBB expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
CN110662762A (zh) 2017-05-24 2020-01-07 诺华股份有限公司 抗体细胞因子移植蛋白和用于治疗癌症的方法
AU2018293627B2 (en) 2017-06-30 2022-07-21 Bayer Animal Health Gmbh New azaquinoline derivatives
CN109836416B (zh) * 2017-11-27 2023-02-03 苏州鹏旭医药科技有限公司 一种化合物的制备方法
US11161851B2 (en) * 2017-11-06 2021-11-02 Suzhou Pengxu Pharmatech Co. Ltd. Processes to produce acalabrutinib
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
PL3820573T3 (pl) 2018-07-10 2024-02-19 Novartis Ag Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2)
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
WO2020128612A2 (en) 2018-12-21 2020-06-25 Novartis Ag Antibodies to pmel17 and conjugates thereof
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2022540935A (ja) 2019-07-17 2022-09-20 アルビナス・オペレーションズ・インコーポレイテッド タウタンパク質標的化化合物および関連する使用方法
WO2021016523A1 (en) * 2019-07-25 2021-01-28 Lanzatech, Inc. Secondary acetate fermentation
EP4007592A1 (en) 2019-08-02 2022-06-08 LanthioPep B.V. Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
US20230056470A1 (en) 2019-12-20 2023-02-23 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4093394A1 (en) 2020-01-20 2022-11-30 Astrazeneca AB Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AU2022258829A1 (en) 2021-04-16 2023-10-26 Novartis Ag Antibody drug conjugates and methods for making thereof
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
WO2024073106A1 (en) * 2022-09-29 2024-04-04 Tract Pharmaceuticals, Inc. Compounds and compositions useful as inhibitors of taps

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3685626T2 (de) * 1985-09-26 1993-01-28 Beckmann Research Inst Of The Sequenzierung von peptiden.
US4935494A (en) * 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
CA2012306A1 (en) * 1989-03-28 1990-09-28 Werner Neidhart Amino acid derivatives
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
SK56798A3 (en) * 1995-10-30 1998-12-02 Smithkline Beecham Corp Protease inhibitors, pharmaceutical composition containing them and their use
WO1998046597A1 (en) 1997-04-14 1998-10-22 Emory University Serine protease inhibitors
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
JP2002533726A (ja) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド 結合のための小有機分子リガンドの同定
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
AU2002253908A1 (en) 2001-02-08 2003-02-17 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
WO2002085897A1 (en) * 2001-04-05 2002-10-31 Alangudi Sankaranarayanan Heterocyclic compounds for aging-related and diabetic vascular complications
CA2449168A1 (en) 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
US20030157522A1 (en) * 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2004005248A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ATE415413T1 (de) 2002-07-15 2008-12-15 Univ Princeton Iap-bindende verbindungen
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
DE60322120D1 (de) 2003-02-07 2008-08-21 Genentech Inc Zusammensetzungen und verfahren für verstärkte apoptose
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
CA2543897A1 (en) 2003-11-13 2005-06-02 Genentech, Inc. Compositions and methods for screening pro-apoptotic compounds
CN1933847A (zh) 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
CA2553874A1 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
US7309792B2 (en) * 2004-03-01 2007-12-18 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
JP5122275B2 (ja) * 2004-03-23 2013-01-16 ジェネンテック， インコーポレイテッド Ｉａｐのアザビシクロ−オクタンインヒビター
US20080242658A1 (en) * 2004-04-07 2008-10-02 Mark G Palermo Inhibitors of Iap
BRPI0511350A (pt) * 2004-07-02 2007-12-04 Genentech Inc composto, métodos de indução da apoptose em uma célula, de sensibilização de uma célula à um sinal apoptótico, de inibição da ligação de uma proteìna iap e de tratamento de uma doença e cáncer e usos de um composto
KR20070043831A (ko) 2004-07-12 2007-04-25 아이디유엔 파마슈티칼즈, 인코포레이티드 테트라펩티드 유사체
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
NZ589670A (en) 2004-12-20 2013-01-25 Genentech Inc Pyrrolidine inhibitors of iap
CA2598995C (en) * 2005-02-25 2014-07-15 Stephen M. Condon Dimeric iap inhibitors
WO2006122408A1 (en) 2005-05-18 2006-11-23 Aegera Therapeutics Inc. Bir domain binding compounds
RU2418807C2 (ru) * 2005-10-25 2011-05-20 Аегера Терапьютикс Инк. Соединения, связывающие bir домены iap
AU2006340014B2 (en) * 2005-12-19 2012-12-20 Genentech, Inc. Inhibitors of IAP
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
MX2008012053A (es) 2006-03-21 2008-12-17 Joyant Pharmaceuticals Inc Promotores de apoptosis de molecula pequeña.
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2102229B1 (en) * 2006-10-12 2014-03-26 Novartis AG Pyrrolydine derivatives as iap inhibitors
KR20090094461A (ko) * 2006-12-19 2009-09-07 제넨테크, 인크. Ｉａｐ의 이미다조피리딘 억제제
AU2009203971A1 (en) * 2008-01-11 2009-07-16 Genentech, Inc. Inhibitors of IAP
CA2730448A1 (en) * 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
CA2730357A1 (en) * 2008-08-16 2010-02-25 Genetech, Inc. Azaindole inhibitors of iap

Also Published As

Publication number Publication date
WO2008134679A1 (en) 2008-11-06
US8907092B2 (en) 2014-12-09
PE20130150A1 (es) 2013-02-27
NZ580226A (en) 2012-11-30
RU2491276C2 (ru) 2013-08-27
JP2010526079A (ja) 2010-07-29
AU2008245447B2 (en) 2014-01-23
BRPI0809867A2 (pt) 2014-09-30
CA2683392A1 (en) 2008-11-06
AU2008245447A1 (en) 2008-11-06
JP5368428B2 (ja) 2013-12-18
KR20100024923A (ko) 2010-03-08
RU2009144094A (ru) 2011-06-10
CN101687787A (zh) 2010-03-31
ZA200906946B (en) 2011-05-25
IL201379A0 (en) 2010-05-31
AU2008245447C1 (en) 2014-11-20
TW200902067A (en) 2009-01-16
MX2009011783A (es) 2009-12-04
TWI432212B (zh) 2014-04-01
AR066348A1 (es) 2009-08-12
CL2008001234A1 (es) 2008-09-22
US20110077265A1 (en) 2011-03-31
EP2148858A1 (en) 2010-02-03
NZ598890A (en) 2013-10-25
EP2148858A4 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
PE20090211A1 (es) Inhibidores de las iap
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
BRPI0617167B8 (pt) sulfonilpirróis como inibidores de hdac's, seu uso, composição farmacêutica e combinação
MX2009006055A (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxam il)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoi co.
TW200736221A (en) Novel pharmaceutical salts and polymorphs of a Factor Xa inhibitor
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
CY1111170T1 (el) Ενωσεις διαρυλ αιθερα ουριας
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
ECSP11011553A (es) Nuevos conjugados, su preparación y su aplicación terapéutica
CO6241190A2 (es) Compuestos para inhibicion enzimatica
HK1133596A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
ATE538099T1 (de) 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
NI201000022A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
UY29007A1 (es) Derivados de 2-carbamida-4-feniltiazol, su preparacinn, y su aplicacinn en terapcutica
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
UY30300A1 (es) Compuestos triarílicos y sus derivados
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
BRPI0606606A2 (pt) composições estáveis contendo prostaglandina
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
AR061134A1 (es) Derivados de tioxantina
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1

Legal Events

Date Code Title Description
FC Refusal